stay updated

Explore the latest news from Khondrion and its team.

Khondrion press releases

June 22, 2021

Khondrion to attend UMDF Mitochondrial Medicine Symposium 2021

Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces its...

April 21, 2021

Khondrion announces first patients dosed in 6-month paediatric Phase II study of sonlicromanol for mitochondrial diseases

Study will examine the pharmacokinetics, safety and efficacy of sonlicromanol, one of the most advanced disease-modifying drug candidates in...

April 6, 2021

Khondrion to present at MITO2i Inaugural Research Symposium on mitochondrial medicine and research

NIJMEGEN, the Netherlands – 6 April 2021: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...

January 18, 2021

Khondrion receives EMA agreement on its Paediatric Investigation Plan for sonlicromanol

Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the...

January 13, 2021

Khondrion announces publication in Scientific Reports outlining an additional anti-inflammatory mode of action for its lead phase IIb-stage drug candidate sonlicromanol

Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces the...

December 18, 2020

Khondrion joins Consortium researching metabolomic processes to predict and prevent COVID-19

Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the...

our stories

October 31, 2015

Khondrion welcomes Hans Schikan

Khondrion Welcomes Hans Schikan, Former Prosensa CEO, to Advisory Board August 10, 2015, NIJMEGEN – Khondrion, the Dutch...